Oscar Fernandez-Capetillo Group
Oscar Fernandez-Capetillo's profile page.
DNA damage is a known cause of cancer and ageing. In this context, drugs that either generate DNA damage or inhibit DNA repair have shown good efficacy in the treatment of tumors, and are the current standard of care in several cases. Still, our knowledge of the specific synthetic lethal interactions that can enhance the efficacy of these treatments is somewhat rudimentary and there is room for improvement. I have previously been involved in the development of DNA repair inhibitors and help them arise clinical phases. At KI, I want to further pursue these translational activities by integrating our research with the national platforms available in the area of drug development. While our research will still have an angle towards DNA damage and repair, we will also explore other health-relevant areas such as the development of immune-modulators or new strategies to treat amyotrophic lateral sclerosis.
In the Media
|Jordi Carreras Puigvert||Project manager|
|Louise Lidemalm||Laboratory technician|
|Maria Häggblad||Research engineer|
|Per Moberg||Research coordinator|
A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors.
Mol. Cell 2016 Apr;62(2):307-13
USP7 is a SUMO deubiquitinase essential for DNA replication.
Nat. Struct. Mol. Biol. 2016 Apr;23(4):270-7
NSMCE2 suppresses cancer and aging in mice independently of its SUMO ligase activity.
EMBO J. 2015 Nov;34(21):2604-19
Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice.
Genes Dev. 2015 Apr;29(7):690-5
The maternal side of Fanconi Anemia.
Mol. Cell 2014 Sep;55(6):803-4